{"id":25174,"date":"2023-10-09T17:58:12","date_gmt":"2023-10-09T12:28:12","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25174"},"modified":"2024-01-05T10:52:56","modified_gmt":"2024-01-05T05:22:56","slug":"primary-hyperoxaluria-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment","title":{"rendered":"Can Novo\u2019s Rivfloza Outperform Its Rival Alnylam\u2019s Oxlumo in Primary Hyperoxaluria Treatment Space?"},"content":{"rendered":"\n

In recent years, Novo Nordisk<\/strong> has been actively addressing the challenges arising from the launch of its highly popular obesity therapy<\/a>, Wegovy<\/strong>. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza<\/strong>, a treatment designed for the rare disease known as primary hyperoxaluria type 1 (PH1). This announcement comes as Novo Nordisk continues to make strides in the field of RNA interference (RNAi) drugs, with Rivfloza being a monthly subcutaneous treatment.<\/p>\n\n\n\n

Following the FDA\u2019s approval of Alnylam\u2019s RNAi therapy Oxlumo<\/strong> in November 2020, this marks the second FDA-approved treatment for the rare and severe disease known as primary hyperoxaluria type 1. Primary hyperoxaluria type 1 is characterized by an excessive production of oxalate, resulting in the formation of kidney stones and a gradual decline in kidney function. It is estimated that the total prevalent population of primary hyperoxaluria<\/a> in 7MM was ~12K<\/strong> in 2021, which is expected to increase at a CAGR of 0.66%, <\/strong>as per DelveInsight. The estimates suggest a higher diagnosed prevalence of primary hyperoxaluria type 1 throughout the 7MM. In the US, out of the total diagnosed prevalent cases of primary hyperoxaluria; 1,629<\/strong> were occupied by primary hyperoxaluria type 1 alone, in the year 2021.<\/p>\n\n\n\n

\"Primary<\/a><\/figure>\n\n\n\n

Novo Nordisk\u2019s groundbreaking RNAi therapeutic, Rivfloza, is the product of their exclusive GalXC RNAi technology platform<\/strong>. Rivfloza is engineered to suppress the activity of lactate dehydrogenase, a liver enzyme crucial in the glyoxylate metabolism pathway. This inhibition aims to curb oxalate overproduction, a concern for patients with PH1<\/a>. The drug\u2019s development was spearheaded by Dicerna Pharmaceuticals, Inc.<\/strong>, which became part of Novo Nordisk through an acquisition in 2021. <\/p>\n\n\n\n

Dicerna had previously investigated the drug in different types of primary hyperoxaluria (PH2 and 3) but eventually shifted its attention exclusively to PH1 based on early data. The FDA has approved Rivfloza for the reduction of urinary oxalate levels in PH1 patients aged 9 and above who still have reasonably healthy kidney function. In a phase II trial, patients on the medication showed a decrease in urinary oxalate excretion when compared to those on a placebo, as reported by Novo. Meanwhile, Alnylam, a competing company, has been actively engaged in promoting Oxlumo since its approval in 2020. By the end of June, over 350 patients worldwide were using the drug commercially, and in the second quarter, it generated $24.2 million<\/strong> in revenue.<\/p>\n\n\n\n

\n

\u201cRivfloza\u2019s FDA approval marks another milestone in Novo Nordisk\u2019s longstanding commitment to advancing research, fostering innovation, and forming strategic collaborations to expand treatment options for rare diseases,\u201d commented <\/em>Blandine Lacroix, Senior Vice President of Strategy and Rare Disease at Novo Nordisk Inc.<\/em><\/strong> \u201cOur dedication to driving positive change for individuals living with rare diseases and addressing the considerable unmet needs of the PH1 community remains unwavering. We eagerly anticipate the availability of our first RNAi treatment for those with PH1, as well as the healthcare professionals who partner in their care.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n

This approval is granted based on data obtained from the pivotal phase II PHYOX clinical trial<\/strong> and interim findings from the ongoing phase III PHYOX extension study<\/strong>. PHYOX successfully achieved its primary objective, demonstrating a significant reduction in 24-hour urinary oxalate (Uox) excretion in patients treated with Rivfloza from Day 90 to Day 180. The percentage change from baseline in 24-hour Uox was assessed through the area under the curve (AUC) analysis. The least-squares (LS) mean difference in AUC24-hour Uox between the Rivfloza and placebo groups was 4976 (95% CI: 2803, 7149; p<0.0001), signifying a significant difference over the 90-day period. The most common adverse reaction, reported in more than 20% of patients, was injection site reactions. Interim results from the PHYOX extension study demonstrate that the reductions in 24-hour Uox excretion were sustained in the 13 PH1 patients who received an additional six months of Rivfloza treatment. Novo Nordisk anticipates making Rivfloza accessible to eligible patients as early as 2024<\/strong>.<\/p>\n\n\n\n

\n

\u201cRNA interference is a tried-and-true therapy option for people with PH1. With the approval of Rivfloza, we now have a novel treatment that reduces oxalate production in a safe and effective manner,\u201d stated <\/em>Dr. David S. Goldfarb, MD, Clinical Chief, Nephrology division, NYU Langone Medical Center and Professor of Medicine and Physiology, NYU Grossman School of Medicine<\/em><\/strong>. \u201cUsing the GalXC RNAi platform, Rivfloza targets the liver-specific lactate dehydrogenase enzyme, which is the final step of oxalate production in PH1.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n

Several other companies across the globe are also diligently working toward the development of novel primary hyperoxaluria treatment therapies<\/a> with a considerable amount of success over the years. Key players, such as Allena Pharmaceuticals (ALLN-177), Biocodex (Stiripentol)<\/strong>, and others, are developing therapies for primary hyperoxaluria treatment. <\/p>\n\n\n\n

\"Emerging<\/figure>\n\n\n\n

ALLN-177 <\/strong>is a crystalline formulation of the enzyme oxalate decarboxylase to specifically degrade oxalate within the GI tract, allowing for its removal from the body through the bowel. This mechanism of action reduces the accumulation of oxalate in the body, limiting the burden on the kidney to filter and then excrete it in the urine. The drug is a first-in-class oral enzyme therapy in late-stage clinical development for the treatment of hyperoxaluria. The drug is being developed in Phase II for primary hyperoxaluria treatment<\/a> by Allena Pharmaceutical.<\/p>\n\n\n\n

Biocodex\u2019s Stiripentol <\/strong>is an anticonvulsant drug used in treating epilepsy as an adjunct therapy along with Clobazam and Valproic acid. This drug is currently approved in the US, Canada, and European countries as oral tablets marketed as Diacomit for the treatment of seizures associated with Dravet syndrome<\/a> in patients 2 years of age and older. In June 2020, orphan designation<\/strong> number EU\/3\/20\/2290 was granted by the European Commission to Biocodex for stiripentol to treat primary hyperoxaluria, and in February 2021, Stiripentol was granted an Orphan Drug designation<\/strong> by the US FDA for primary hyperoxaluria treatment.<\/p>\n\n\n\n

The anticipated launch of these therapies will not only give tough competition to Novo\u2019s Rivfloza and Alnylam\u2019s Oxlumo but also increase the primary hyperoxaluria treatment market size in the coming years. As per DelveInsight analysis, the primary hyperoxaluria market size<\/a> in the 7MM is estimated to be USD 81 million<\/strong> in 2021, which is further expected to increase by 2032. It will be interesting to watch how Rivfloza and Oxlumo will retain their positions in the evolving primary hyperoxaluria treatment space.<\/p>\n\n\n\n

\"Primary<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a treatment designed for the rare disease known […]<\/p>\n","protected":false},"author":14,"featured_media":25175,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1482,877,21338,18800,18801,21337,18437,21339],"industry":[17225],"therapeutic_areas":[17240,17238,17234],"class_list":["post-25174","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-alnylam-pharmaceuticals","tag-novo-nordisk","tag-oxlumo","tag-primary-hyperoxaluria","tag-primary-hyperoxaluria-market","tag-primary-hyperoxaluria-treatment","tag-primary-hyperoxaluria-type-1","tag-rivfloza","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nPrimary Hyperoxaluria Treatment Showdown: Rivfloza vs. Oxlumo<\/title>\n<meta name=\"description\" content=\"FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Primary Hyperoxaluria Treatment Showdown: Rivfloza vs. Oxlumo\" \/>\n<meta property=\"og:description\" content=\"FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-09T12:28:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-05T05:22:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/09143416\/primary-hyperoxaluria-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Primary Hyperoxaluria Treatment Showdown: Rivfloza vs. Oxlumo","description":"FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment","og_locale":"en_US","og_type":"article","og_title":"Primary Hyperoxaluria Treatment Showdown: Rivfloza vs. Oxlumo","og_description":"FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.","og_url":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-10-09T12:28:12+00:00","article_modified_time":"2024-01-05T05:22:56+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/09143416\/primary-hyperoxaluria-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment","url":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment","name":"Primary Hyperoxaluria Treatment Showdown: Rivfloza vs. Oxlumo","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/09143416\/primary-hyperoxaluria-treatment.webp","datePublished":"2023-10-09T12:28:12+00:00","dateModified":"2024-01-05T05:22:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/09143416\/primary-hyperoxaluria-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/09143416\/primary-hyperoxaluria-treatment.webp","width":772,"height":482,"caption":"primary-hyperoxaluria-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/09143416\/primary-hyperoxaluria-treatment-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Oxlumo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Hyperoxaluria<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Hyperoxaluria Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Hyperoxaluria Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Primary Hyperoxaluria Type 1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rivfloza<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">Oxlumo<\/span>","<span class=\"advgb-post-tax-term\">Primary Hyperoxaluria<\/span>","<span class=\"advgb-post-tax-term\">Primary Hyperoxaluria Market<\/span>","<span class=\"advgb-post-tax-term\">Primary Hyperoxaluria Treatment<\/span>","<span class=\"advgb-post-tax-term\">Primary Hyperoxaluria Type 1<\/span>","<span class=\"advgb-post-tax-term\">Rivfloza<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Oct 9, 2023","modified":"Updated on Jan 5, 2024"},"absolute_dates_time":{"created":"Posted on Oct 9, 2023 5:58 pm","modified":"Updated on Jan 5, 2024 10:52 am"},"featured_img_caption":"primary-hyperoxaluria-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25174"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25174\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25175"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25174"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25174"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}